In this issue:
Polatuzumab vedotin, obinutuzumab and lenalidomide for FL
Low-dose dasatinib in older patients with CML
Zanubrutinib, obinutuzumab, and venetoclax for CLL
DA-EPOCH-R for primary mediastinal B-cell lymphoma
Cardiovascular disease risk after radiotherapy for early-stage HL
Enasidenib + azacitidine for acute myeloid leukaemia
Acalabrutinib vs ibrutinib in previously treated CLL
Nonmyeloablative allogeneic stem cell vs autologous transplant relapsed FL
Escalated-R-CHOP-21 for diffuse large B-cell lymphoma in elderly males
Ponatinib in chronic-phase CML
Please login below to download this issue (PDF)